Latest Cystic Fibrosis Foundation Stories
Aptalis CF Cycle for Life Tour Series Supports Lifesaving Cystic Fibrosis Research BETHESDA, Md., July 6, 2011 /PRNewswire-USNewswire/ -- The Cystic Fibrosis Foundation today announced that Aptalis Pharma will be the 2011 national title sponsor for its premier cycle series--Aptalis CF Cycle for Life.
Kids from 20 States Make Case for Drug Funding and Access to Care for Fatal Disease BETHESDA, Md., June 22, 2011 /PRNewswire-USNewswire/ -- Teens from across the United States whose siblings, cousins and other loved ones have cystic fibrosis will urge elected officials in Washington, D.C., to fund government agencies that are vital to drug research and development.
ABBOTT PARK, Ill., June 14, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved an infant-specific dose of CREON(R) (pancrelipase) Delayed-Release Capsules to treat exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF).
BETHESDA, Md., June 10, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Inc.
MONMOUTH JUNCTION, N.J., June 10, 2011 /PRNewswire/ -- Insmed Incorporated (Nasdaq CM: INSM), a biopharmaceutical company, today announced positive data through six treatment cycles (72 weeks total duration) of its Phase 2 clinical trial program for ARIKACEÂ® (liposomal amikacin for inhalation) in cystic fibrosis (CF) patients with Pseudomonas lung infections.
Pool Fun Raises Money for Cystic Fibrosis This Summer (PRWEB) June 09, 2011 This summer, swimmers and pool enthusiasts can make a splash for a very worthy cause with BioGuard Splash for CF, a nationwide fundraiser in support of cystic fibrosis (CF) patients and their local hospital care centers.
BETHESDA, Md., June 9, 2011 /PRNewswire-USNewswire/ -- Vertex Pharmaceuticals Incorporated and the Cystic Fibrosis Foundation today announced promising results from an ongoing Phase 2 study evaluating combinations of VX-770 and VX-809, potential medicines designed to treat the defective protein that causes cystic fibrosis. The study enrolled 62 people with two copies of the most common CF mutation, known as Delta F508.
Bluegreen Corporation supports the Cystic Fibrosis Foundation with cash contributions and sponsorship of local events. Boca Raton, Fl (PRWEB) June 01, 2011 Bluegreen Corporation (NYSE: BXG), a leading provider of Colorful Places to Live and Play, today announced that a team of walkers from its Boca Raton, Florida corporate headquarters helped raise money for the Cystic Fibrosis Foundation by taking part in the Great Strides Walk event held at Florida Atlantic University on May 1, 2011....
- The act of sweetening by admixture of some saccharine substance.